Long‐term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis

Abstract

Long-term (12-month) administration of fluticasone furoate 110 microg od revealed an AE profile typical of the intranasal corticosteroid class in both adult and adolescent patients with PAR, with no evidence of clinically relevant systemic corticosteroid exposure.